Erratum: Peripheral Measurable Residual Disease Activity Assessment by MALDI-TOF Mass Spectrometry in Patients With Newly Diagnosed Multiple Myeloma in the Phase III GMMG-HD7 Trial

Journal of Clinical Oncology 2026 Open access

Read full text
Authors: Jia Xiang Jin, Varun R. Ginde, Stefanie Huhn, Philipp Reichert, Uta Bertsch, Roland Fenk, Britta Besemer, Amelie Boquoi, Roland Schroers, Ivana von Metzler, Mathias Hänel, Christoph Mann
+27 more Lisa B. Leypoldt, Bernhard Heilmeier, Christof Scheid, Thorsten Peters-Regehr, Igor W. Blau, Carsten Müller-Tidow, Steffen Luntz, T Holderried, Karolin Trautmann‐Grill, Deniz Gezer, Maika Klaiber-Hakimi, Martin Müller, Evgenii Shumilov, Wolfgang Knauf, Christian S. Michel, Thomas Geer, Hendrik Riesenberg, Christoph Lutz, Marc Steffen Raab, Niels Weinhold, Martin Hoffmann, Axel Benner, Peter Findeisen, Katja C. Weisel, Hans Jürgen Salwender, Elias Karl Mai, Hartmut Goldschmidt
DOI: 10.1200/jco-26-01346
Cited by: 2

Fields of Study & Subjects

Multiple Myeloma Research and Treatments Malaria Research and Control Mass Spectrometry Techniques and Applications

Publication details

Journal / source
Journal of Clinical Oncology
Publisher
American Society of Clinical Oncology (ASCO)
Volume
44
Issue
20
Pages
1955–1955
Publication date
8 June 2026
Language
EN